05:21 AM EDT, 06/14/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that results from the phase 2 MagnetisMM-3 study of ELREXFIO in patients with heavily pretreated relapsed or refractory multiple myeloma showed a median overall survival of 24.6 months, with median progression-free survival of 17.2 months.

After more than two years of follow-up in the MagnetisMM-3 trial, the overall response rate for patients on ELREXFIO was 61%, the company said.